pharmaphorum
MARCH 28, 2022
Built under a government tender, AION Labs comprises four large international pharma companies – AstraZeneca , Merck, Pfizer , and Teva – and another core partner, the Israel Biotech Fund. At times, companies invest millions of dollars in developing and studying a therapy that may find to be ineffective. The partnership.
pharmaphorum
MARCH 19, 2021
The oceans of health data out there can be overwhelming for pharma companies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is very real, says Lifebit CEO, Dr Maria Chatzou Dunford. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 19, 2023
Bioinformatics and genetic sequencing are starting to be placed front and centre of public research programmes as scientists from around the world recognise the substantial benefits of knowledge sharing and resource pooling when it comes to genetic science. The tide has been turning in the worlds of diagnostics and drug development.
pharmaphorum
APRIL 7, 2022
During the initial stage of the collaboration, Ares developed a an AI-powered anti-infectives platform using microbiological lab techniques and bioinformatics that can be used to identify effective antimicrobial compounds or combinations against specific pathogens, which Sandoz can use to inform its “portfolio and commercial decisions.”
pharmaphorum
OCTOBER 20, 2021
The trial – which will be supported by pharma company Eisai and Ionian University in the US – will see if the test can identify people who have mild cognitive impairment (MCI) due to Alzheimer’s disease.
Drug Discovery World
MAY 1, 2024
This is reflected in collaboration and investment patterns; in 2023, Antiverse, a biotechnology company developing a computational antibody drug discovery platform, raised seed funding totalling £1.4 million, comprising new investment and match funding from the UKI2S Innovate Accelerator.
pharmaphorum
APRIL 1, 2021
They go into bioinformatics”. In the past couple of years, Turbine worked with a number of big pharma companies, including Bayer, and has also started building its own pipeline, including a target delivering new biological insight in PARP inhibitor resistance. “We They go into bioinformatics.”. So what do they do?
Expert insights. Personalized for you.
97 
Let's personalize your content